金斯瑞生物科技(01548.HK):傳奇生物向美國證交會提交註冊聲明
格隆匯5月29日丨金斯瑞生物科技(01548.HK)宣佈,傳奇生物已於2020年5月29日(紐約時間)就其價格區間為18.00美元至20.00美元的美國存托股份向證交會提交註冊聲明。受傳奇生物及承銷商訂立的承銷協議的最終條款規限及視乎市況而定,發售預計將包括由傳奇生物首次公開發售出售的1842.5萬股新美國存托股份。承銷商亦將可選擇購買最多達276.38萬股額外美國存托股份以補足超額分配。每股美國存托股份將代表兩股傳奇生物股份。
在發售完成的前提下,於發售完成時,傳奇生物將按經調整以反映美國存托股份對普通股比率的每股公開發售價向公司發行及出售一定數目的傳奇生物股份,總價為1200萬美元。
根據第15項應用指引的規定,董事會建議透過實物分派的方式,給予合資格股東一定數目分派美國存托股份的保證配額,從而妥善顧及股東的利益。非合資格股東將不會獲得分派美國存托股份,而於相關記錄日期持有規定的最低股份數目(有關數目將由公司適時釐定)的非合資格股東將可收取現金以代替彼等有權獲取的相關數目的分派美國存托股份。根據公司日期為2020年5月26日的公告,預期董事會將於2020年6月5日通過一項決議案,藉以考慮及批准建議將透過實物分派方式支付的有條件特別股息的宣派,而根據上市規則第13.43條發出通告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.